<DOC>
	<DOCNO>NCT01151904</DOCNO>
	<brief_summary>This study evaluate safety efficacy patient switch latanoprost monotherapy combination therapy latanoprost COMBIGAN® ( brimonidine 0.2 % /timolol 0.5 % fix combination ophthalmic solution ) chronic angle closure glaucoma .</brief_summary>
	<brief_title>Study Brimonidine Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost Glaucoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Angle-Closure</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate , Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patient administer latanoprost eye drop affect eye ( ) least 12 week prior study Patient must least partially responded latanoprost require IOP lower eye drop Diagnosis chronic angleclosure glaucoma Patients use COMBIGAN® past must discontinue due adverse event lack efficacy . Known allergy hypersensitivity COMBIGAN® Corneal abnormality would preclude accurate IOP reading Any active ocular disease glaucoma ocular hypertension Ocular surgery within past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>